Author: admin

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 31, 2025–
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Dec. 31, 2025 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 10 individuals hired by Sarepta in the fourth quarter of 2025. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received in the aggregate 55,118 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee’s continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta’s common stock.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit www.sarepta.com or follow us on LinkedIn, X, Instagram and Facebook.

Internet Posting of Information

We routinely post information that may be important to investors in the ‘For Investors’ section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251231461456/en/

Investor:
Ian Estepan, 617-274-4052

iestepan@sarepta.com

Media:
Tracy Sorrentino, 617-301-8566

tsorrentino@sarepta.com

Source: Sarepta Therapeutics, Inc.

Several marijuana products sold by a single company to dispensaries across Colorado have potentially unsafe pesticides that exceed the legal limits, state health and business regulators said in a health advisory on Wednesday.

Vapes and infused pre-rolled marijuana produced by CC Brands, LLC, doing business as “Stash House CO,” have been voluntarily recalled, according to the Colorado Department of Revenue and Colorado Department of Public Health and Environment, but the affected batches were produced between Feb. 27 and Dec. 11, 2025, and are sold in 295 stores across the state, those agencies said.

Those stores span almost every corner of the state and include around 75 stores in Denver, 55 in Colorado Springs, 11 in Aurora, nine in Fort Collins, seven in Boulder, and are sold in popular dispensary chains like Native Roots, The Green Solution, Star Buds, Green Dragon, and Igadi.

A full list of these stores can be found here.

Reached by phone, a representative for CC Brands, LLC, said there are no longer impacted batches of the products on shelves. Every batch was pulled from shelves within the last two weeks or so, he said.

Anyone who does have those vapes or pre-rolls from the affected batch numbers, however, is urged to return them to the store where they were purchased or dispose of them, the state’s Marijuana Enforcement Division said. Those batch numbers are as follows:

Contaminated Production Batches:

Potentially Contaminated Production Batches:

• 1340
• 1341
• 1342
• 1343
• 1348
• 1352
• 1355
• 1375

“Individuals who experience adverse health effects after consuming the affected product should seek medical attention immediately and report the event to the MED by submitting an MED Reporting Form,” the state’s health advisory reads.

The tested batches found levels beyond the regulatory limits of the chemicals chlorfenapyr and fluopyram.

Marijuana products have been recalled in Colorado for various reasons before, and in 2015, there were at least two recalls due to pesticides — one in September of that year and one in October — although other recalls have been due to yeast and mold, among other reasons. You can see a full list of marijuana health and safety advisories here.

LONDON/NEW YORK (Reuters) – Oil prices fell on Wednesday and recorded an annual loss of nearly 20%, as expectations of oversupply increased in a year marked by wars, higher tariffs, increased OPEC+ output and sanctions on Russia, Iran and Venezuela.

Brent crude futures shed about 19% in 2025, the most substantial annual percentage decline since 2020 and its third straight year of losses, the longest such streak on record. US West Texas Intermediate crude logged an annual decline of almost 20%.

On the last day of the year, Brent futures settled at $60.85 a barrel, down 48 cents, or 0.8%. US WTI crude fell by 53 cents, or 0.9%, to settle at $57.42 a barrel.

BNP Paribas commodities analyst Jason Ying anticipates Brent will dip to $55 a barrel in the first quarter before recovering to $60 a barrel for the rest of 2026 as supply growth normalises and demand stays flat.

“The reason why we’re more bearish than the market in the near term is that we think that US shale producers were able to hedge at high levels,” he said.

“So the supply from shale producers will be more consistent and insensitive to price movements.”

US crude stocks fell last week, but distillate and gasoline inventories grew more than expected, according to data from the US Energy Information Administration.

“It was a modestly supportive report on crude drawdown, but the inners of the report are not so great and it will probably be a rough January and February with the holidays in the rearview mirror,” said John Kilduff, partner at Again Capital Markets.

Crude inventories fell by 1.9 million barrels to 422.9 million barrels in the week ended December 26, the EIA said, compared with analysts’ expectations in a Reuters poll for an 867,000-barrel draw.

US gasoline stocks rose by 5.8 million barrels in the week to 234.3 million barrels, the EIA said, compared with analysts’ expectations for a 1.9 million-barrel build.​ Distillate stockpiles, including diesel and heating oil, rose by 5 million barrels to 123.7 million barrels, versus projections of a 2.2 million-barrel rise.

Oil production in the US hit a record in October, according to the latest data from the EIA.

Oil markets had a strong start to 2025 when former President Joe Biden ended his term by imposing tougher sanctions on Russia, disrupting supplies to major buyers China and India.

The impact of the war in Ukraine on energy markets intensified when Ukrainian drones damaged Russian infrastructure and disrupted Kazakhstan’s oil exports.

The 12-day Iran-Israel conflict in June added to the threats to supply by disrupting shipping in the Strait of Hormuz, a major route for global seaborne oil, which fanned oil prices.

In recent weeks, OPEC’s biggest producers, Saudi Arabia and the United Arab Emirates, have become locked in a crisis over Yemen. US President Donald Trump has ordered a blockade on Venezuelan oil exports and threatened another strike on Iran.

OPEC+ ACCELERATED OUTPUT INCREASES

But prices eased after OPEC+ accelerated its output increases this year and as concerns about the impact of US tariffs weighed on global economic and fuel demand growth.

OPEC+, the Organization of the Petroleum Exporting Countries and allied producing nations, paused oil output hikes for the first quarter of 2026 after releasing some 2.9 million barrels per day into the market since April. The next OPEC+ meeting is on January 4.

Most analysts expect supply to exceed demand next year, with estimates ranging from the International Energy Agency’s 3.84 million barrels per day to Goldman Sachs’ 2 million bpd.

“If the price really has a substantial fall, I would imagine you will see some cuts (from OPEC+),” said Martijn Rats, Morgan Stanley’s global oil strategist. “But it probably does need to fall quite a bit further from here on – maybe in the low $50s.”

“If today’s price simply prevails, after the pause in Q1, they’ll probably continue to unwind these cuts.”

John Driscoll, managing director of consultancy JTD Energy, expects geopolitical risks to support oil prices even though market fundamentals point to oversupply.

“Everybody’s saying it’ll get weaker into 2026 and even beyond,” he said. “But I wouldn’t ignore the geopolitics, and the Trump factor is going to be playing out because he wants to be involved in everything.”